Daniel S. Lorrain, Chief Scientific Officer at Contineum Therapeutics, Inc. (CTNM), sold 37,179 shares at $16.04 ($595K) on 2026-06-30, disclosed to the SEC on 2026-07-02.
Scheduled sale ($595k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.04 | 28,826 | $462K | 77.8% |
| 2 | $15.67 | 5,852 | $92K | 15.4% |
| 3 | $16.24 | 2,501 | $41K | 6.8% |
| Total | $15.99 avg | 37,179 | $595K | 100% |
| Filing → |
| CTNM | SELL | 2026-05-01 | $55K | — | Filing → |
| CTNM | SELL | 2026-04-06 | $56K | — | Filing → |
| CTNM | SELL | 2026-03-02 | $63K | — | Filing → |